NASDAQ:KZR Kezar Life Sciences (KZR) Stock Price, News & Analysis $4.01 +0.03 (+0.73%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Kezar Life Sciences Stock (NASDAQ:KZR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kezar Life Sciences alerts:Sign Up Key Stats Today's Range$3.93▼$4.0250-Day Range$3.98▼$4.7952-Week Range$3.62▼$9.18Volume23,246 shsAverage Volume38,709 shsMarket Capitalization$29.31 millionP/E RatioN/ADividend YieldN/APrice Target$39.50Consensus RatingHold Company Overview Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Read More Kezar Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreKZR MarketRank™: Kezar Life Sciences scored higher than 73% of companies evaluated by MarketBeat, and ranked 254th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingKezar Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageKezar Life Sciences has only been the subject of 1 research reports in the past 90 days.Read more about Kezar Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kezar Life Sciences are expected to decrease in the coming year, from ($4.39) to ($8.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kezar Life Sciences is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kezar Life Sciences is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKezar Life Sciences has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Kezar Life Sciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.98% of the float of Kezar Life Sciences has been sold short.Short Interest Ratio / Days to CoverKezar Life Sciences has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Kezar Life Sciences has recently increased by 51.78%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKezar Life Sciences does not currently pay a dividend.Dividend GrowthKezar Life Sciences does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.85 Percentage of Shares Shorted5.98% of the float of Kezar Life Sciences has been sold short.Short Interest Ratio / Days to CoverKezar Life Sciences has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Kezar Life Sciences has recently increased by 51.78%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A News SentimentKezar Life Sciences has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Kezar Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,531.00 in company stock.Percentage Held by Insiders10.40% of the stock of Kezar Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.90% of the stock of Kezar Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kezar Life Sciences' insider trading history. Receive KZR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address KZR Stock News HeadlinesKezar Life Sciences Says FDA Lifts Clinical HoldJuly 16, 2025 | marketwatch.comKezar Life Sciences stock gains after FDA lifts partial clinical holdJuly 16, 2025 | uk.investing.comSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strategy: Sell This, Buy That. In his newest presentation, Eric reveals 7 new trade ideas—pairing overhyped, vulnerable stocks with lesser-known opportunities showing real upside. These contrarian picks come from the same approach that helped him beat Wall Street legends 10-to-1 in Portfolios with Purpose.August 8 at 2:00 AM | InvestorPlace (Ad)Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune HepatitisJuly 15, 2025 | businesswire.comKezar Life Sciences Inc. Research & Ratings | KZR | Barron'sJuly 13, 2025 | barrons.comKZR | Kezar Life Sciences Inc. Stock Overview (U.S.: Nasdaq) - Barron'sJune 30, 2025 | barrons.comKezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | businesswire.comKezar Life Sciences price target lowered to $7 from $9 at Wells FargoMarch 27, 2025 | markets.businessinsider.comSee More Headlines KZR Stock Analysis - Frequently Asked Questions How have KZR shares performed this year? Kezar Life Sciences' stock was trading at $6.72 at the start of the year. Since then, KZR shares have decreased by 40.3% and is now trading at $4.01. How were Kezar Life Sciences' earnings last quarter? Kezar Life Sciences, Inc. (NASDAQ:KZR) issued its earnings results on Tuesday, May, 13th. The company reported ($2.27) EPS for the quarter, topping analysts' consensus estimates of ($2.56) by $0.29. When did Kezar Life Sciences' stock split? Kezar Life Sciences's stock reverse split on the morning of Wednesday, October 30th 2024.The 1-10 reverse split was announced on Monday, October 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Kezar Life Sciences IPO? Kezar Life Sciences (KZR) raised $70 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO. Who are Kezar Life Sciences' major shareholders? Kezar Life Sciences' top institutional investors include Peapod Lane Capital LLC (1.57%). Insiders that own company stock include Morningside Venture Investment, Mark C Schiller and Pichi Luo Chiang. View institutional ownership trends. How do I buy shares of Kezar Life Sciences? Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kezar Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kezar Life Sciences investors own include Predictive Oncology (POAI), Ford Motor (F), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Bank of America (BAC), Abbott Laboratories (ABT) and Zomedica (ZOM). Company Calendar Last Earnings5/13/2025Today8/08/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KZR CIK1645666 Webwww.kezarlifesciences.com Phone(650) 822-5600FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Price Target for Kezar Life Sciences$39.50 High Price Target$70.00 Low Price Target$9.00 Potential Upside/Downside+892.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($10.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.74 million Net MarginsN/A Pretax MarginN/A Return on Equity-61.15% Return on Assets-50.27% Debt Debt-to-Equity Ratio0.04 Current Ratio7.09 Quick Ratio7.09 Sales & Book Value Annual Sales$7 million Price / Sales4.16 Cash FlowN/A Price / Cash FlowN/A Book Value$16.02 per share Price / Book0.25Miscellaneous Outstanding Shares7,310,000Free Float6,546,000Market Cap$29.09 million OptionableNot Optionable Beta0.65 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:KZR) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kezar Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.